Management of Prostate Cancer

Bolla, Michel|van Poppel, Hendrik

ISBN 10: 3319427687 / ISBN 13: 9783319427683

Published by Springer International Publishing, 2017

About this Item

Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Provides an exhaustive review of the state of the art in the management of prostate cancerEmphasizes a multidisciplinary approachExplains the roles of the different therapies and active surveillanceAddresses diagnosis and clinical wo.

Seller Inventory # 123031931

Bibliographic Details

• Title: Management of Prostate Cancer
• Publisher: Springer International Publishing
• Publication Date: 2017
• Language: English
• ISBN 10: 3319427687
• ISBN 13: 9783319427683
• Binding: Gebunden
• Edition: 2nd Edition
• Condition: New
• Seller catalogs:
  • Mathematik/Naturwissenschaften/Technik/Medizin

About this title

Synopsis

This book, now in an extensively revised second edition, provides an exhaustive review of the state of the art in the management of prostate cancer, from screening to treatment, with emphasis on a multidisciplinary approach. The editors are very excited about the outstanding new or updated contributions from the different expert authors.

The opening chapters address basic aspects including epidemiology, pathology, biology, genetics, and chemoprevention. The role of individual and mass screening is carefully appraised, and extensive attention is devoted to diagnosis and clinical work-up by means of recently implemented investigations such as multiparametric MRI and choline PET-CT.

The use of active surveillance is examined in detail. Subsequent chapters discuss the different therapies that may be employed: open and minimally invasive, including robot-assisted, radical prostatectomy, the various forms of radiation treatment, high-intensity focused ultrasound, cryotherapy, hormonal manipulations, chemotherapy, targeted therapies, and immunotherapy. Up-to-date results from practice-changing phase III randomized clinical trials are included and special insights are provided into the interpretation of results and the patient’s perspective.

About the Author

Michel Bolla M.D. is Professor for Radiation Oncology and Oncology. He received his medical degree at the Joseph Fourier University of Grenoble and had his radiation therapy training at the University Hospital of Grenoble and the Comprehensive Cancer Centre Georges François Leclerc in Dijon. He was appointed Professor in 1986 and was particularly involved in the structuring of Oncology at the Grenoble University Hospital: Head of the Radiation Oncology Department (1997-2009), President of the Federation of Oncology (2000-7), President of the Arc Alpin Oncology Network (2002 -2009). Professor Bolla was nominated as President of the French Society of Radiation Oncology (2006-7): he was particularly involved in the definition of radiotherapy quality criteria (Plan Cancer I) and served as project-manager of the French Radiation Therapy Observatory, under the French National cancer Institute and the French Society of Radiation Oncology umbrella. After serving as Secretary ofthe Radiation Oncology Group of the European Organization on Research and Treatment of Cancer (EORTC) since 1991, Professor Bolla was elected chairman of the Radiation Oncology Group (1997-2000) then member of the EORTC Board (2000-2006). The focus of his clinical research for many years is prostate cancer: indications of adjuvant radiotherapy after radical prostatectomy, combination of androgen deprivation with external irradiation for locally advanced prostate cancer, which earned him several publications on the New England Journal of Medecine and the Lancet. In 2009 the steering Committee of the 2^ND European Multidisciplinary Meeting on Urological Cancers (EAU,ESMO, ESTRO) honoured him as recepient of an award for Excellence in Radiation Oncology.As regard screening, he was one of the promoters of breast, cervix and colon and rectal cancers mass screening for women (50-74 years) in Isère (1990) and he is now trying to implement prostate cancer screening in men.

Professor Hein Van Poppel M.D., PhD., is the Chair­man of the Department of Urology at the Univers­ity Hospital Gasthuisberg, Katholieke Universiteit Leuven, the largest urological training institute in Belgium.He graduated in General Surgery in 1980, in Urology in 1983 and joined the Academic Unit at the KU Leuven after 2 years of postgraduate training in London, Barcelona, Copenhagen, Mainz and Rotter­dam. In 1988, he obtained a PhD in Medical Sciences.  He became a Fellow of the European Board of Urology in 1992 and a full Professor of Urology in 1993.He is a board member of the European Association of Urology (EAU), and of the International Consultation on Urological Disease (ICUD).  He is study coordinator and treasurer of the EORTC GU Group. He is Chairman of the Educational Office of the EAU and director of the European School of Urology (ESU). He is also member of the American Association of Genito Urinary surgeons (AAGUS). He is president of the Belgian Society of Urology (BVU), Chairman of the Scientific Committee of Europa Uomo and Faculty Member of the European Society of Medical Oncology (ESMO). The clinical focus of his work is on genitourinary cancer management and on primary and salvage surgery for kidney, bladder, prostate and testicular malignancies.He is member of numerous scientific organisations in Europe and worldwide and reviewer for the most prominent urological peer review journals.He has published more than 200 papers as first author on uro-oncological surgery and has co-authored more than 250 other papers.